

ABBOTT INDIA LIMITED**DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2019 TO MARCH 31, 2020***(All amounts in Rs. Lakhs, unless otherwise stated)***A) Parties where control exists :****Ultimate Holding Company :** Abbott Laboratories, USA**Holding Company :** Abbott Capital India Ltd., UK**B) Other related parties with whom transactions have taken place during the year :****I) Fellow subsidiaries :**

British Colloids Ltd., U.K.

Abbott Healthcare Products Ltd., U.K

Abbott Healthcare Private Ltd., India

Abbott International LLC, USA

Abbott Products Operations AG., Switzerland

Abbott Laboratories (Singapore) Pte Ltd., Singapore

Abbott Manufacturing Pte Ltd., Singapore

Abbott GmbH, Germany

Alere Medical Private Limited, India

Abbott Laboratories S.A., Switzerland

Abbott Laboratories S.A., Dubai

Abbott Laboratories Services LLC, Sri Lanka Branch

St Jude Medical India Private Limited, India

II) Key Management personnel and Independent directors:

Mr. Ambati Venu, Non-executive Director (ceased to be the Managing Director effective close of business hours on February 29, 2020)

Mr. Munir Shaikh, Chairman

Mr. Rajiv Sonalker, Whole-Time Director

Mr. Krishna Mohan Sahni, Independent Director (ceased to be the Director effective close of business hours on October 28, 2019)

Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)

Mr. Rajendra Shah, Independent Director (ceased to be the Director effective close of business hours on March 31, 2019)

Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019)

Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019)

C) Transactions during the year :**I) Transactions with the Holding Company during the year**

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Capital India Ltd., UK		
Remittance of dividend	69,67.41	58,95.50

II) Transactions with Fellow Subsidiaries during the year**i) Remittance of dividend :**

	For the year ended March 31, 2020	For the year ended March 31, 2019
British Colloids Ltd., U.K.		
Remittance of dividend	9,55.50	8,08.50
Abbott Healthcare Products Ltd., U.K		
Remittance of dividend	24,34.22	20,59.72

ii) Sales to fellow subsidiaries :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India		
Sales of stock-in-trade	56,85.73	56,24.56
Sales of raw materials	47,11.52	46,79.97
Sale of capital goods	-	32.99
Abbott Products Operations AG., Switzerland		
Sales of stock-in-trade	85.54	-

iii) Purchases from fellow subsidiaries :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India		
Purchase of raw materials	4,91.58	4,93.78
Purchase of stock-in-trade	145,05.60	120,73.92
Abbott Products Operations AG., Switzerland		
Purchase of raw materials	297,28.34	296,21.37
Purchase of stock-in-trade	80,03.73	35,46.38

ABBOTT INDIA LIMITED
DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2019 TO MARCH 31, 2020
(All amounts in Rs. Lakhs, unless otherwise stated)
iv) Purchase of capital goods from fellow subsidiary :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Alere Medical Private Limited, India Purchase of capital goods	-	12.09

v) Other expenses to fellow subsidiaries :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India Promotional expenses	62.81	1,54.74
Conversion charges	16,63.05	9,15.63
Payment of lease liabilities *	32,88.60	-
Finance costs *	1,97.67	-
Electricity and communication expenses	72.00	72.00
Alere Medical Private Limited, India Promotional expenses	5.63	2.22

* In the current year, the Company adopted Ind AS 116 'Leases', with the date of initial application as April 1, 2019.

vi) Interest from fellow subsidiary :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Alere Medical Private Limited, India Interest income on loan (Refer Note 25)	-	12,54.80

vii) Reimbursements to and from fellow subsidiaries :

	Reimbursement to		Reimbursement from	
	For the year ended March 31, 2020	For the year ended March 31, 2019	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India Shared and support services	10,14.00	10,14.00	-	-
Rent expenses	-	32,88.60	-	-
Market research and other expenses	-	-	15.17	13.15
Abbott International LLC, USA Employee benefits expense, travel and other expenses	28.45	34.04	-	-
Abbott Manufacturing Pte Ltd., Singapore Employee benefits expense, travel and other expenses	-	-	-	8.47
Abbott Laboratories (Singapore) Pte Ltd., Singapore Employee benefits expense, travel and other expenses	39.66	12.52	26.79	19.01
Abbott Products Operations AG., Switzerland Employee benefits expense, travel and other expenses	-	-	1,60.37	1,20.35
Abbott Laboratories S.A., Switzerland Employee benefits expense, travel and other expenses	-	-	9.51	6.30
Abbott GmbH, Germany Employee benefits expense, travel and other expenses	-	-	10.49	-
Abbott Laboratories Services LLC, Sri Lanka Branch Employee benefits expense, travel and other expenses	-	-	25.30	-

viii) Income from fellow subsidiaries :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India Shared and support services (Refer Note 24 (b))	16,26.00	16,26.00
Rent income (Refer Note 25)	1,14.52	1,14.53
Abbott Products Operations AG., Switzerland Shared and support services (Refer Note 24 (b))	3,70.75	5,08.51
Abbott Laboratories S.A., Dubai Shared and support services (Refer Note 24 (b))	1,26.94	33.60
Abbott Laboratories (Singapore) Pte Ltd., Singapore Shared and support services (Refer Note 24 (b))	1,26.94	33.60
St Jude Medical India Private Limited, India Shared and support services (Refer Note 24 (b))	61.56	-

ix) Lease liabilities from fellow subsidiary :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Abbott Healthcare Private Ltd., India Recognition of lease liabilities *	134,55.09	-

* In the current year, the Company adopted Ind AS 116 'Leases', with the date of initial application as April 1, 2019.

ABBOTT INDIA LIMITED
DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE PERIOD APRIL 1, 2019 TO MARCH 31, 2020
(All amounts in Rs. Lakhs, unless otherwise stated)
x) Key management personnel remuneration* :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Mr. Ambati Venu, Non-executive Director (ceased to be the Managing Director effective close of business hours on February 29, 2020)	7,14.73	6,50.75
Mr. Rajiv Sonalker, Whole-Time Director	3,29.82	3,04.76

* During the year, as a part of the 'Long Term Incentive Program', Restricted Stock Units of Abbott Laboratories, USA carrying perquisite value of **Rs.3,64.49 Lakhs** (March 31, 2019 : Rs.2,69.88 Lakhs) have been granted to the above employees. Also refer Note 37 (b).

Also, provision for post employment benefits as contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis are not included in remuneration to key management personnel.

xi) Non-Executive, Other Directors' sitting fees :

	For the year ended March 31, 2020	For the year ended March 31, 2019
Mr. Munir Shaikh, Chairman	10.50	15.00
Mr. Rajendra Shah, Independent Director (ceased to be the Director effective close of business hours on March 31, 2019)	-	16.00
Mr. Krishna Mohan Sahni, Independent Director (ceased to be the Director effective close of business hours on October 28, 2019)	9.00	14.50
Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)	13.50	13.00
Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019)	12.00	-
Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019)	5.50	-

D) Outstanding :

	As at March 31, 2020	As at March 31, 2019
Trade payable to fellow subsidiaries (Refer Note 19)		
Abbott Products Operations AG., Switzerland	86,30.69	109,66.44
Abbott Healthcare Private Ltd., India	14,69.88	18,05.45
Alere Medical Private Limited, India	-	3.88
Abbott Laboratories (Singapore) Pte Ltd., Singapore	2.74	-
	<u>101,03.31</u>	<u>127,75.77</u>
Lease Liabilities to fellow subsidiary (Refer Note 41)		
Abbott Healthcare Private Ltd., India	133,17.75	-
	<u>133,17.75</u>	<u>-</u>
Other payable to fellow subsidiary (Refer Note 20)		
Abbott Healthcare Private Ltd., India	44.66	44.66
	<u>44.66</u>	<u>44.66</u>
Trade receivables from fellow subsidiaries (Refer Note 9)		
Abbott Healthcare Private Ltd., India	24,76.57	54,45.04
Abbott Products Operations AG., Switzerland	26.47	-
	<u>25,03.04</u>	<u>54,45.04</u>
Other receivables from fellow subsidiaries (Refer Note 13)		
Abbott Products Operations AG., Switzerland	58.61	47.68
Abbott Healthcare Private Ltd., India	66.30	1,17.97
Abbott Laboratories Services LLC, Sri Lanka Branch	2.01	-
Abbott International LLC, USA	5,36.04	3,98.31
Abbott Laboratories S.A., Switzerland	-	6.13
Abbott Laboratories S.A., Dubai	20.05	32.99
Abbott Laboratories (Singapore) Pte Ltd., Singapore	23.42	10.86
Abbott GmbH, Germany	11.16	-
St Jude Medical India Private Limited, India	66.49	-
	<u>7,84.08</u>	<u>6,13.94</u>
Loan and deposit to fellow subsidiaries		
Abbott Healthcare Private Ltd., India (Refer Note 5, 7, 14 and 41)	14,77.10	14,67.67

Terms and conditions of transactions with related parties :

All transactions with related parties are made in the ordinary course of business and the same is at arm's length. Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. The Company has not recorded any impairment for receivables. This assessment is undertaken each financial year through examining the financial position of the related parties and the market in which related parties operate.